One Of The Nourishing Kidney And Promoting Blood Recipes Combined With Shuzizaba Clinical Research On The Treatmentof Postmenopausal Osteoporosis

Objective:By observing and comparing the clinical efficacy of combined use of kidney-tonifying and blood-circulating prescription and denosumab versus simple use of denosumab in the treatment of postmenopausal patients with osteoporosis,this thesis discusses in depth the therapeutic effects and safety of the kidney-tonifying and blood-circulating prescription on clinical symptoms,quality of life,and bone metabolism indicators in improving postmenopausal patients with osteoporosis.Method:Select 64 postmenopausal osteoporosis patients who are receiving the Orthopedics Department of Yunnan Provincial Traditional Chinese Medicine Hospital from November2021 to June 2022.The patients are randomly divided into a control group(33 cases)and a treatment group(31 cases).Control group: basic treatment,including oral calcium carbonate D3 tablets and vitamin D3 drops,as well as subcutaneous injection of denosumab injection.Treatment group: For the first three months of the treatment period,the treatment group receives the addition of a kidney-tonifying and blood-circulating prescription on the base of the control group treatment.For the following three months of the treatment period,the treatment group continues to receive oral administration of calcium carbonate D3 tablets and vitamin D3 drops.The course of treatment of both groups is 6 months.The changes of the total score of TCM syndrome,the efficacy of TCM syndrome,VAS score,SF-36 score,bone mineral density level and bone metabolism indicators(β-CTX,ALP,N-MID)of the patients are observed and recorded at each observation point before and after drug treatment.Finally,all data are statistically analyzed and processed.Result:The changes in observation indicators of two groups of patients after treatment are as follows: 1.The total score of TCM syndromes at each observation point in both groups of patients decreased to varying degrees compared with that before treatment(P<0.001),and the TCM compound group was superior to the basic treatment group in the comparison between the two groups at each observation point(P<0.05).2.TCM syndrome efficacy:After 3 months of intervention treatment,the effective rate was 33.33% in the basic treatment group and 74.19% in the TCM compound group.After 6 months of intervention treatment,the effective rate was 57.58% in the basic treatment group and 80.65% in the TCM compound group.The efficacy of the TCM compound group was superior to that of the basic treatment group(P<0.05).3.VAS score: The VAS score at each observation point of both groups of patients decreased to varying degrees compared with that before treatment(P<0.001).The analgesic effect of the TCM compound group was superior to that of the basic treatment group in the comparison between the two groups at each observation point after the treatment(P<0.05).4.SF-36 score: The SF-36 scores at each observation point of both groups of patients were higher than before treatment(P<0.05).After 3months of treatment,the TCM compound group showed greater improvement than the basic treatment group in the aspects of physical pain,physiological function,overall health,and emotional function in the comparison between the two groups(P<0.05).After 6months of treatment,the TCM compound group showed greater improvement than the basic treatment group in the aspects of physical pain,physiological function,and overall health in the comparison between the two groups(P<0.05).5.Bone mineral density level:The bone mineral density level of both groups of patients increased to varying degrees after 6 months of treatment compared to before treatment(P<0.001).There was no statistically significant difference in bone density level between the two groups after treatment(P>0.05).6.Bone metabolism indicators: After treatment,the β-CTX level in each observation point of the basic treatment group decreased significantly compared to before treatment(P<0.001),while the ALP and N-MID levels did not differ significantly from before treatment(P>0.05);After treatment,the β-CTX and N-MID level in each observation point of the TCM compound group decreased to varying degrees compared with that before treatment(P<0.001),and the ALP level decreased compared with that before treatment after 3 months of treatment(P<0.05).Three months after stopping oral administration of traditional Chinese medicine compound,the ALP level increased to the pre-treatment level(P>0.05).In the comparison between the two groups after treatment,there was no significant difference in β-CTX level(P>0.05),and the improvement of N-MID level in the TCM compound group was superior to that in the basic treatment group(P<0.001).The improvement in ALP level in the TCM compound group during the use of the traditional Chinese medicine compound was superior to that in the basic treatment group(P<0.05),and there was no significant difference in ALP level between the two groups after three months of stopping the traditional Chinese medicine compound(P>0.05).Conclusion:Both the kidney-tonifying and blood-circulating prescription and the denosumab injection can be used to treat postmenopausal osteoporosis.During the six-month treatment period,the combined use of the kidney-tonifying and blood-circulating prescription and denosumab injection shows a significant therapeutic effect,which is more conducive to improving the clinical symptoms,enhancing the quality of life,improving the bone metabolism indicator,and increasing the bone density level of patients.Moreover,the clinical medication is relatively safe and worthy of promotion and application.